Clinical trials: Solid Organ Malignancies, open to volunteers
Non-melanoma Skin Cancer, Carcinoma, Squamous Cell
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection.
- Conditions
- Non-melanoma Skin Cancer, Carcinoma, Squamous Cell, Carcinoma, Basal Cell, Keratinocyte Carcinoma
- Trial name
- SPRINTR (NCT05955924)
- Testing
- Nicotinamide
- Where
- 7 sites in Canada
- Volunteers
- 396 people
- Sponsor
- Women's College Hospital
Chronic Disease, Immunocompromised
Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients
AMBU-VAX is a prospective, single-center observational study designed to develop and implement an organizational model for delivering recommended vaccinations within a hospital setting.
- Conditions
- Chronic Disease, Immunocompromised, HIV Infection, Chronic Kidney Disease
- Trial name
- AMBU-VAX (NCT07391046)
- Testing
- Hospital-Based Vaccination Pathway
- Volunteers
- 1,500 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pancreatic Cancer
Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)
In the case of large tumors or tumors closely adjacent to organs at risk, ablative doses offered by stereotactic body radiation therapy (SBRT) could not be delivered.
- Trial name
- NCT06427460
- Testing
- Central-boost ablative dose delivered by stereotactic body radiation therapy
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Changhai Hospital
Infectious Diseases, Immunocompromised Host
Metagenomic Sequencing Across the Infectious Disease Risk and Care Continuum
The AXIS Network is a prospective, multicenter observational registry designed to generate real-world evidence on the use of metagenomic sequencing in clinical practice across a broad range of patient populations, infectious…
- Conditions
- Infectious Diseases, Immunocompromised Host, Opportunistic Infections
- Trial name
- AXIS (NCT07825714)
- Volunteers
- 10,000 people
- Sponsor
- Karius, Inc.
Adenovirus, Cytomegalovirus Infections
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV, and EBV, in subjects who have previously received any type of…
- Conditions
- Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- NCT06909110
- Testing
- Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jessie L. Alexander
Human Papillomavirus Infection, Anal HPV Infection
Epidemiology of Anal Human Papillomavirus Carriage in Female Solid Organ Transplant Recipients With More Than 10 Years of Immunosuppression
Anal canal cancer is primarily associated with persistent infection by high-risk human papillomavirus (HR-HPV), particularly HPV-16.
- Conditions
- Human Papillomavirus Infection, Anal HPV Infection, Human Papillomavirus 16 Infection
- Trial name
- EPAHTOS (NCT07858201)
- Testing
- Anal Self-Sampling for High-Risk HPV Detection
- Volunteers
- 190 people
- Sponsor
- University Hospital, Montpellier
CMV Retinitis
Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.
The goal of this exploratory clinical study is to evaluate the safety and efficacy of Cytomegalovirus-Specific T cells (LB-DTK-CMV) to treat patients diagnosed with antiviral-resistant and refractory cytomegalovirus retinitis.
- Trial name
- NCT07679412
- Testing
- LB-DTK-CMV
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- LucasBio
PTLD, Epstein Barr Virus (EBV) Infection
Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia
People who have received a solid organ transplant can develop ongoing Epstein-Barr virus (EBV) infection in the blood, which increases the risk of a serious cancer called post-transplant lymphoproliferative disorder (PTLD).
- Conditions
- PTLD, Epstein Barr Virus (EBV) Infection, Solid Organ Transplant
- Trial name
- NCT07614282
- Testing
- Rituximab
- Volunteers
- 28 people
- Sponsor
- Jennifer Amengual
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
Insomnia, Malignant Solid Neoplasm
THC Versus THC/CBD Versus Placebo to Improve Sleep Quality for Patients With Solid Organ Cancer and Insomnia
This phase II trial compares THC versus (vs.) THC with CBD vs. placebo to improve sleep quality for patients with solid organ cancer and insomnia.
- Trial name
- NCT07565974
- Testing
- Biospecimen Collection, Single Agent Therapy
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Mayo Clinic
Cutaneous Squamous Cell Carcinoma, Skin Cancer
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC).
- Trial name
- NCT07426484
- Testing
- Cosibelimab, Prednisone, Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how well it works in preventing Epstein-Barr virus (EBV) infection and…
- Conditions
- Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm
- Trial name
- NCT06741072
- Testing
- Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cancer, Surgery
A Platform Study for solId orgaN CancERs
Generating bespoke biosampling protocols for individual tumour specific translational projects is onerous, cumbersome and inefficient.
- Trial name
- PINCER (NCT05650125)
- Testing
- Biosampling
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)").
- Conditions
- Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
- Trial name
- BrILliance (NCT06413680)
- Testing
- REGN10597, Cemiplimab
- Where
- 11 sites in United States
- Volunteers
- 240 people
- Sponsor
- Regeneron Pharmaceuticals
EBV Viremia, CMV Viremia
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
This study is evaluating the safety and effectiveness of virus-specific cytotoxic T lymphocytes (vCTLs) for treating difficult-to-control viral infections caused by cytomegalovirus (CMV), adenovirus (ADV), Epstein-Barr virus…
- Conditions
- EBV Viremia, CMV Viremia, BK Viremia, Adenovirus
- Trial name
- NCT07873970
- Testing
- Virus-Specific Cytotoxic T Lymphocytes (vCTLs)
- Volunteers
- 35 people
- Sponsor
- Children's Hospital of Philadelphia
Solid Tumor
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis
This trial applies a uniform approach to re-irradiation for planning and diagnostic image fusion, dose summation, dose calculations, and follow up for tumor control and detailed toxicity analysis of serial Organs At Risk (OARs).
- Trial name
- REDIRICT (NCT05301101)
- Testing
- Re-irradiation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Medical College of Wisconsin
Anal Cancer
Host Genome Methylation: a Screening Tool in Anal Cancer Detection
In January 2023, the first recommendations for anal cancer screening were issued by the French National Society of Coloproctology (SNFCP).
- Trial name
- AMethysT (NCT06792604)
- Testing
- Anal self-sampling (smear), HPV questionnaire
- Where
- 9 sites in France
- Volunteers
- 770 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by…
- Conditions
- Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx
- Trial name
- NCT03093909
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Organ Transplant Recipient, Skin Cancer
The Organ Transplant Recipient HPV and Skin Cancer Study
Solid organ transplant recipients (OTRs) receive lifelong immunosuppressive therapy, which puts them at increased risk of cutaneous and mucosal cancers.
- Conditions
- Solid Organ Transplant Recipient, Skin Cancer, Skin Dysplasia, HPV Infection
- Trial name
- NCT05284877
- Testing
- No intervention
- Where
- 3 sites in Denmark
- Volunteers
- 1,500 people
- Sponsor
- Merete Haedersdal
Donors, Organ Donor
Rapid Processing and Immunohistochemistry Method for Optimising Diagnosis Time in Solid Organ Donors, Suspected Malignancy
Comparison of the diagnostic yield of intra-operative histological analysis of donor tissue with suspected neoplasia performed with the standard method versus the experimental method, which involves optimisation of sample…
- Conditions
- Donors, Organ Donor, Organ Transplants
- Trial name
- NCT06734091
- Testing
- PrestoCHILL
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna